Jazz Pharmaceuticals (Ireland)

Recent papers from Jazz Pharmaceuticals (Ireland)

1. Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trialThe Lancet · 2025
2. Optimising CPX-351 (liposomal cytarabine-daunorubicin) treatment for t-AML/AML-MRC patients in the outpatient setting: a modified Delphi consensusAnnals of Hematology · 2026
3. Oxidant‐Expedited Synthesis of H‐PhosphonatesEuropean Journal of Organic Chemistry · 2026
4. Nilotinib in chronic myeloid leukemia: clinical value, real-world challenges, and the potential of nilotinib tablets to improve therapeutic outcomesExpert Review of Hematology · 2026
5. Next-generation strategies for PROTAC formulation: mechanistic insights and advanced formulation technologiesExpert Opinion on Drug Delivery · 2026
6. Innovative Peptide Formulations for Cardiovascular Diseases Using Supercritical CO2: A Comprehensive Review and Potential ApplicationsEuropean Journal of Pharmaceutical Sciences · 2026
7. Coumarins Disrupt Cell–Cell Communication and Virulence in Priority Pathogens: Targeting the PQS Signalling System in Pseudomonas aeruginosaMicrobial Biotechnology · 2026
8. Transcriptomic analyses of molecular subsets and correlations with clinical outcomes from the phase 3 IMforte study of lurbinectedin (lurbi) + atezolizumab (atezo) maintenance treatment (Tx) in extensive-stage small-cell lung cancer (ES-SCLC).Journal of Clinical Oncology · 2026
9. Safety and pharmacokinetics (PK) of lurbinectedin (lurbi) in pediatric patients (pts) with relapsed/refractory (R/R) solid tumors and preliminary antitumor activity in pediatric and young adult pts with R/R Ewing sarcoma (EwS): Results from a phase 1 study.Journal of Clinical Oncology · 2026
10. Potential of a bacterial immunomodulatory enzyme to restore health in a Th17 cytokine cocktail-induced skin psoriasis modelTissue and Cell · 2026
11. Inhalable dry powder formulations of the commercialised form of Deoxyribonuclease I - a dried alternative for the treatment of cystic fibrosisEuropean Journal of Pharmaceutical Sciences · 2026
12. CPX-351 Selectively Benefits Patients with AML and Myelodysplasia-Related Mutations in the Pivotal Randomized TrialBlood Advances · 2026
13. Landmark analysis of overall survival (OS) by objective response in patients (pts) with previously treated, advanced HER2-positive biliary tract cancer (BTC): Post hoc analysis of the HERIZON-BTC-01 trial.Journal of Clinical Oncology · 2026
14. Evaluating Arrhythmia Risk in Patients with Chronic Obstructive Pulmonary Disease Treated with Aclidinium/Formoterol Fumarate and Other Inhaled Bronchodilators: A Post-Authorization Safety StudyInternational Journal of COPD · 2026
15. CPX-351 vs. conventional chemotherapy cardiotoxicity in high-risk AML: a post hoc phase III trial analysisCardio-Oncology · 2025
16. Progress on drug nanoparticle manufacturing: exploring the adaptability of batch bottom-up approaches to continuous manufacturingJournal of Drug Delivery Science and Technology · 2025
17. Flucloxacillin formulation odour acceptability: A human sensory assessmentJournal of Drug Delivery Science and Technology · 2025
18. Lanthanide(III) Metal‐Organic Frameworks (Ln=Gd, Tb, Dy) Based on a C₃ Symmetrical Tricarboxylate LinkerEuropean Journal of Inorganic Chemistry · 2024
19. Efficacy and Safety of Lower-Sodium Oxybate in an Open-Label Titration Period of a Phase 3 Clinical Study in Adults with Idiopathic HypersomniaNature and Science of Sleep · 2022
20. Can recombinant technology address asparaginase Erwinia chrysanthemi shortages?Pediatric Blood & Cancer · 2021